Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan

University of Khartoum

Status and phase: Unknown; Phase 4

Conditions: Malaria

Treatments: Drug: Dihydroartemisinin- piperaquine; Drug: artemether- lumefantrine

Study type: Interventional

Funder types: Other

Identifiers

NCT01075945

DP v AL01aasudan (Other Identifier)

DP v AL01

wadadam

Details and patient eligibility

About

Dihydroartemisinin- Piperaquine is not inferior to artemether-lumefantrine

Enrollment: 140 estimated patients

Sex: All

Ages: 5 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Uncomplicated malaria

Exclusion criteria

• Severe cases
• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

140 participants in 2 patient groups

Dihydroartemisinin- piperaquine

Experimental group

Description:

orally tablets

Treatment:

Drug: artemether- lumefantrine

Drug: Dihydroartemisinin- piperaquine

artemether- lumefantrine

Active Comparator group

Description:

oral tablets

Treatment:

Drug: artemether- lumefantrine